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Abstract
Background: Metatypical cell carcinoma can be considered as a new entity of skin cancer, being
an intermediate typology between basal cell carcinomas and squamous cell carcinomas. The
behaviour of the metatypical cell carcinoma lies between these two varieties of skin cancer. It is
difficult to perform a differential diagnosis based on morphological and clinical features – therefore
it is only possible by accurate histology.
Methods: The authors have retrospectively analysed clinical records of 240 patients who were
affected by metatypical skin cancer and who were treated by surgery, radiotherapy and
chemotherapy.
Results: MTC affected more males than females (62.5% vs 37.5%) than males. The most affected
site was the cervicofacial area, 71.7%; then the trunk, 10%; the limbs, 9.6%; the scalp 3.7%; and other
regions 5%. A recurrence occurred in 24 cases (10%), mainly in head and neck area.
Conclusion: In this manuscript, the authors have emphasised the importance of conducting a
differential diagnosis, and the importance of the specific treatment for metatypical skin cancer, even
though more clinical studies and long-term follow-ups are required before establishing specific
guidelines.
Background
Nonmelanoma skin cancers are the most common type of
cancer, with over 1.3 million new cases diagnosed and
treated annually, in the Western Coutries alone, which
indicates an increasing prevalence [1-4]. Non-melanoma
skin cancer is composed of different tumours, 95% of
which consist of basal or squamous cell carcinoma [1-4].
Although advances in molecular genetics have localised
mutations for numerous nonmelanoma skin cancers, the
cause remains multifactorial [2-5]. Moreover, environ-
mental (U.V. radiation) and lifestyle factors, as well as the
aging population, certainly play a key part in the onset of
a tumour [2-4]. Although skin cancers are more common
in Caucasians, they are also prevalent in people with a
dark complexion (e.g. African-Americans) [6-9].
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Basal cell carcinoma tends to develop on the head and
neck, and other sun-exposed areas, whereas squamous
cell carcinoma has a strong link with advanced age (i.e.
>40 years), and ultraviolet exposure. They are commonly
present on non-facial sites and have a propensity to
develop in sun-exposed areas of the body. Both basal cell
and squamous cell carcinomas may, however, also
develop on non-sun-exposed areas [1-3].
Basosquamous carcinoma, also known as metatypical car-
cinoma (MTC), is a non-melanoma skin cancer that
shares the features of both the squamous and basal cell
carcinomas. This tumour should be considered as another
skin cancer, with its own particular characteristics, such as
behaviour and histological features.
As it is an intermediate typology between basal cell carci-
noma (BCC) and squamous cell carcinoma (SCC), the
metatypical carcinoma simulates the BCC clinically and
morphologically, but compared with BCC it is more
aggressive and prone to metastasise [10-15]. Therefore,
the separation of MTC from the group of basaliomas is of
primary importance, as this tumour is capable of metasta-
sizing, whereas MTC diagnosis is difficult because it is
similar to basalioma clinically and hystologically [10-12].
The definition of the basosquamous cell carcinoma and
the presence of intermediate areas of differentiation of
this tumour have been emphasised by some authors, and
it has been suggested that metastatic-basal-cell carcinoma
and MTC may be the same tumour [13-17].
However, there are some studies about the mitotic rate –
in cases of MTC and BCC cases of basalioma – that have
shown this finding to be adequate for differential diagno-
sis of these tumours. The values of the mitotic regimen in
MTC differ from the similar types of values in the basali-
oma: the mitotic activity; the specific content of dividing
cells at the stage of metaphase; and the rate of pathologic
mitoses increased considerably [13-17].
MTC, however, has been poorly defined clinically and
pathologically, and a result has no general acceptance in
medical literature [18-24].
Concerning the surgical treatment, it has been discovered
that a significant proportion of excised BCC demonstrates
histological positive-surgical margins. This high incidence
of positive-surgical margins for excised BCC may be
caused by the irregular infiltration of these tumours. As a
result, the surgeon cannot clinically detect the subclinical
spread. So, the inadequate excision of a BCC and of the
MTC that is clinically similar is possible. Furthermore, the
more appropriate margin is still controversial for the BBC,
as it is for the MTC.
We retrospectively reviewed the cases of MTC-operated
patients during a seven-year period (1996 to 2003) at the
Department of Plastic Surgery of University of Rome "La
Sapienza", to find the rates of recurrence and metastasis of
these lesions within this group, and to see whether or not
the histological presentations (mixed type and intermedi-
ate type [Figures 1 and 2, respectively]) were more appar-
ent in a particular subgroup of age or sex.
Materials and methods
Another 240 patients with cases of MTC affecting different
regions (the trunk, upper and lower limbs, scalp, neck,
and facial), were retrospectively analysed from 1996 to
2003 at the Department of Plastic Surgery of the Univer-
sity of Rome "La Sapienza". The study included 90
females and 150 males, between the ages of 27 and 95.
The average age was 70.5 years.
All tumours were measured and excision margins were
marked. The borders were marked on the basis of visual or
palpable alterations on surface contours, consistent with a
non-melanotic skin carcinoma. The minimum surgical
margin was that of the short axis of the ellipse. Tumour
size, location, and the availability of loose donor skin at
the surgical margins were taken into account to help deter-
mine the appropriate surgical margin for each tumour,
and to provide an ideal surgical closure while clearing the
tumour in a single excision.
Ellipses were designed as an eccentric parallelogram
before infiltration with local anaesthesia and without
stretching the skin. A precise margin of apparently healthy
skin was taken around the outer border of the ink marking
Histological appearance of a metatypical cell carcinoma Figure 1
Histological appearance of a metatypical cell carci-
noma. A: Mixed type hematoxylin eosin stain 20 ×. B: Inter-
mediate type hematoxylin eosin stain 20 ×.Journal of Experimental & Clinical Cancer Research 2008, 27:65 http://www.jeccr.com/content/27/1/65
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the tumour: Peripheral clearance margins of 3 mm around
tumours in facial areas and 5 mm margins around lesions
in other sites. Although, in cases with a clinical history of
rapid growth, in which a standard 5 mm surgical margin
have been adopted for head and neck lesions and 10 mm
for other regions.
Full-depth dermal incisions, perpendicular to the skin sur-
face, were made along the outer inked edge of each
marked ellipse. These ellipses were removed beneath the
dermis.
A histological determination was made to determine
whether there was a tumour present at the surgical mar-
gins. If a tumour was present, additional skin was
removed and histologically verified until clear margins
were obtained.
Diagnosis was obtained by histology. Management fore-
saw surgical excision, radiotherapy and chemotherapy. A
follow-up was conducted up to five years after surgery.
Results
In this study, MTC affected more males than females
(62.5% vs 37.5%). The most affected site was the cervico-
facial area, 71.7% (172 cases); then the trunk, 10% (24
cases); the limbs, 9.6% (23 cases); the scalp 3.7% (9
cases); and other regions 5% (12 cases) (Table 1). In all
cases, diagnosis of MTC was confirmed.
The average diameter of the lesions was 1.3 cm, the largest
tumour measured 5 × 3 cm, and the smallest 0.6 × 0.4 cm.
The margins differed based on the anatomic location and
on the growth pattern based on clinical history. The mean
surgical margin was 3 to 5 mm on the facial area and 5 to
10 mm on the other areas. The wider excision in cases of
incomplete eradication of a MTC was 5 mm around the
entire scar of the previous surgery (Table 2).
Histological examination showed different subtypes such
as mixed (32%), intermediate (68%). Ulceration was
occasionally present (10%) and an infiltrative aspect has
been observed in 2.5% of patients. 62% of patients with
mixed metatypical carcinoma were males, with an average
age of 68.6 years, and 38% females with an average age of
71.8 years. Intermediate metatypical carcinoma was
found in 68% of cases, striking mainly males (66%) with
an average age of 69.6 years, and 34% females with an
average age of 72.7 years (Table 3). A recurrence occurred
in 24 cases (10%), mainly in head and neck -these were re-
operated using a wider excision (Table 3).
Discussion
The incidence of non-melanoma skin cancer varies based
on geographic location, with the highest rate of 1 to 2%
per year in regions of high ultraviolet exposure, such as
Australia [3]. Among the more common BCC and SCC,
the MTC has different rates of local recurrence, disease
spread and mortality. Differential diagnosis between MTC
and the group of basaliomas is difficult for the similar
clinical findings, but it is imperative for the risk of metas-
Histological appearance of a metatypical cell carcinoma Figure 2
Histological appearance of a metatypical cell carci-
noma. Intermediate type hematoxylin eosin stain 20 ×.
Table 1: Patient's population group and areas affected by MTC.
Areas Males Females tot
Cervico-facial 107 (44,6%) 65 (27,1%) 172 (71,7%)
Trunk 16 (6,6%) 8 (3,3%) 24 (10%)
Limbs 14 (5,8%) 9 (3,7%) 23 (9.6%)
Scalp 5 (2%) 4 (1,6%) 9 (3.7%)
Other regions 8 (3,3%) 4 (1,6%) 12 (5%)
tot 150 (62,5%) 90 (37,5%) 240 (100%)
Table 2: Surgical margins adopted for MTC excision.
Standard Rapid-growth history
Primary excision H&N 3 mm 5 mm
Primary excision body 5 mm 10 mm
Wider excision 5 mm 5 mmJournal of Experimental & Clinical Cancer Research 2008, 27:65 http://www.jeccr.com/content/27/1/65
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tases associated with the MTC if compared to BCC [6-
8,10-15]. Then MTC should be considered as another
entity of non-melanoma skin cancer, as intermediate
typology between BCC and SCC.
In our study group we found more lesions on the head
and neck area (71.6%) compared to other areas like the
trunk (10%) or the limbs (9.6%), scalp (3.8%), and other
zones (5%). Among these cases the intermediate metatyp-
ical carcinoma was found in 68% of cases, striking mainly
younger males (66%; average age of 69.6 years) than
females (34%; average age of 72.7 years), whereas the
mixed metatypical carcinoma was found in 32% of cases,
62% were males (average age of 68.6 years), and 38%
females (average age of 71.8 years). We can confirm in our
study that MTC was more prevalent in old ages and facial/
head-neck areas as SCC, but there was no significant pre-
dilection of histological type for any sex in our study, as it
was not a representative population.
In an another study, mixed metatypical carcinoma was
found in 24% of cases, with an average age of 71 years,
and prevalence on head (81%); while intermediate
metatypical carcinoma, was found in 76% of cases, strik-
ing mainly the head (70%), then the trunk (19%) and
limbs (9%). These findings are similar to our results.
Concerning the surgical excision margins to be adopted
for MTC excision, we reviewed the literature of the BCC
and SCC standard surgical margin and recurrence rate
risk.
Histological positive surgical margins of excised BCC are
considerably high (>16% for head and neck region) [25-
30]. Perhaps, some reports show very high recurrence
rates, reaching up to 52% of inadequate excision of all
BCC excised [31,32]. Lesions in the temporal and fore-
head areas are particularly prone to recur, or meta-
chronous basal cell carcinoma may occur in these areas
[33]. So, clinically, for BCC and SCC larger peripheral
margins are marked on head and neck areas to avoid
recurrence and then increase the risk of disease spread.
Studies report wide ranges of surgical margins, ranging
from 2 to 10 mm or more, for BCC due to the clinical dif-
ficulties in judging the margins of basal cell carcinomas
[34,35]. Different studies with a 3 to 5 mm margin for pri-
mary BCC excisions report incomplete excisions of about
4% for either basal cell or squamous cell carcinoma, only
in cases with clear clinical tumour margins as for the nod-
ular basal cell carcinoma [36].
Other studies have found a considerably higher percent-
age of lesions that need a wider margin, while Goldberg
[37,38] recommends 2 to 5 mm surgical margins, and 10
mm for infiltrative lesions.
For SCC, the anatomic locations influenced tumour
aggressiveness, and the reconstructive surgery possibili-
ties. The mucosal variant requires special attention
because of its high propensity to recur and metastasise
[25]. Squamous cell carcinoma of the ear also requires a
special mention, as it represents one of the most common
origins for metastasis, and is the anatomic site with the
highest rate of recurrence (18.7%) [26]. Tumour thickness
has also been shown to correlate with metastatic rates
[25,26].
Although no satisfactory reports have been published on
squamous cell carcinoma, in terms of an optimal margin
to predict recurrence rates, subsets of squamous cell carci-
noma may still recur, despite having a complete excision
[39]. For SCC the degree of cellular differentiation repre-
sented by keratinisation has been correlated with tumour
aggressiveness, as poorly differentiated squamous cell car-
cinoma has a reported recurrence rate of 28.6%, and met-
astatic rate of 32.8%, where as well-differentiated
squamous cell carcinoma is 13% and 9.2%, respectively
[40].
The suggested standard surgical margin for primary non-
melanoma skin cancers is 4 mm [36,41,42]. This surgical
margin of 4 mm would have achieved an optimal excision
in 96% of basal cell and 97% of squamous cell carcinoma
[36,41,42]. However, studies have shown that only 7% of
small, well-circumscribed primary BCCs, infiltrate beyond
1 mm of their clinical margins [43], thus being in agree-
ment with Asadi and colleagues [36].
Based on these studies, and on clinical experience with
SCC and BCC, we adopted a surgical margin of 3 to 5 mm
for the head and neck lesions and of 5 to 10 mm in the
other areas, using the wider margin in cases of rapid
growth clinical history.
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Having clear histological margins does not always guaran-
tee that a tumour will not reappear because the presence
of discontinuous subclinical tumour extension could give
rise to tumour recurrence [44]. In these cases, neither con-
ventional surgery [45] nor Mohs' micrographic surgery
[46,47] can be expected to resect such discontinuous
tumours, unless fortuitously wide margins of conven-
tional surgery clearance include such tumour discontinu-
ities. A prospective randomised study of local recurrence
after both techniques did not show that one method was
statistically superior to the other during a 30-month fol-
low-up period [34].
The recurrence rate of our study group for a 3–5 mm and
a 5–10 mm surgical excision, occurred in 24 cases (10%),
these were re-operated with a wider excision until obtain-
ing free of disease surgical margins. This could lead us to
confirm the tendency of MTC to have the aggressiveness of
SCC.
Although mortality rates are low for both, they are signif-
icantly higher for squamous cell carcinoma than for basal
cell carcinoma. Mortality from squamous cell carcinoma
is frequently secondary to metastases of tumour originat-
ing from the ear [48].
In addition to the morbidity and mortality associated
with squamous cell carcinoma of the ear, squamous cell
carcinoma of the lip carries the highest rate of metastasis
(13.7%) [49].
Basal cell carcinoma is rarely metastatic, with a reported
incidence of 0.0028% to 0.55% [13,14]. Although varia-
ble, the risk of metastasis for squamous cell carcinoma is
greater, estimated at approximately 5%, with a range of
0.5% to 6%, and some reports reaching 16% [50-52].
The metatypical carcinoma is aggressive and metastatic,
with rates of metastasis reported up to 7.4%, in between
the SCC and the BCC metastatic rate [53-55].
In our five-year follow up, mortality did not occur, but
four patients (4/240 1,6%) needed positive regional
lymph node dissection.
Conclusion
MTC requires a different management compared to that
of the BCC, particularly if it has been incompletely
excised. However, these differential diagnoses can occa-
sionally pose difficult morphological problems. The
stated distinctions are clinically important because the
risk of progressive disease is significantly higher with
squamous carcinoma of the skin and MTC than of the
BCC.
The excision should be wider than the ones adopted with
BCC's excision, particularly as the lesion has a history of
fast growth. However, in medical literature, no guidelines
regarding MTC excision margins have been established
yet. On the basis of our experience, we believe that a wider
excision should be adopted when dealing with a MTC that
has been histologically proved, and a special follow up
should be conducted. As a clinical differential diagnosis
cannot be surely achieved, it is more appropriate to avoid
a wide excision and skin sacrifice, especially with facial
areas. Due to MTC having a higher growth rate than BCC,
an adequate excision for early onset lesion is necessary.
The MCC diagnosis and treatment in the early stages can
lead to a satisfactory recovery.
However, further clinical studies with long-term follow-
up will still be required to clear any doubts the manage-
ment of the MCC may have.
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